All News
Exploring Idiopathic Myopathies
2026 EULAR Press Release
Idiopathic inflammatory myopathies (IIM) are a heterogenous group of autoimmune conditions with substantial morbidity. EULAR in collaboration with the American College of Rheumatology (ACR) introduced classification criteria for the major subgroups in 2017,1 but there is a need for contemporary real-world data to understand the burden – and well as new ways of assessing disease activity.
Read Article
The RADIAL study integrates point-of-care ultrasound into the diagnostic work-up for suspected inflammatory arthritis. 601 patients, 6 diagnoses, 1 algorithm.
Result: NPV above 90% for most diagnoses. The Double Contour sign for gout: OR 52.66. PPV for RA: 0.85.
Ultrasound at
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
#OP0345 Lung US outperformed clinical risk scores for detecting RA-assoc ILD, incl in asymptomatic patients. Compared with HRCT, LUS achieved 95.4% sensitivity & 77.7% specificity. Combining LUS with risk scores incr sensitivity to 100% for ILD detection. #EULAR2026 @RheumNow
Mrinalini Dey DrMiniDey ( View Tweet)
Live vaccinations in infants antenatally exposed to bDMARDs
⬇️⬇️
#WIN session @lauraandreoli80
#EULAR2026 @RheumNow https://t.co/84MCwb2fbT
Nelly ZIADE 🍀 Nellziade ( View Tweet)
Dr. Laura Andreoli shares this slide showing the impact of rheumatic disease in reproductive health as described by Dr. MOstensen.
These interplay of factors affect patients and should be taken into consideration when managing fertility & pregnancy.
@RheumNow #EULAR2026 https://t.co/fB9kuD4kXo
sheila RHEUMarampa ( View Tweet)
Double targeted therapy in refractory SpA/PsA.
76 patients, 17 Spanish centres, up to 6 years follow-up. Median 4 prior biologics.
Remission achieved in 55.6% during follow-up. 28.6% in remission at final visit.
ASDAS improved significantly from 3 months, sustained to 5 https://t.co/g1IPstYYuX
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
Starting the “Imaging innovation in RA” session with #OP0343: Singapore investigators developed an AI-based thermography model to detect RA wrist inflammation using thermal hand images, achieving an AUC of 0.87 against ultrasound power doppler as reference. #EULAR2026 @RheumNow https://t.co/2v39E6VOWB
Mrinalini Dey DrMiniDey ( View Tweet)
10yr ffup data on 49pts from the OG CRESPA study (GOL vs PBO in very early pSpA):
81.6% (40/49) were in clinical remission
15 pts on drug-free remission
21 pts w/remission on meds still on GOL, no unSSAEs
Early aggressive tx is key!
AbsPOS0931 @RheumNow #EULAR2026 https://t.co/HrTF5XtAZt
Links:
sheila RHEUMarampa ( View Tweet)
This study describes the SIJ differences in axSpA vs. non-axSpA pts with CBP
axSpA: BME w/ widespread distribution & inflamm⬇️ over time
non-axSpA: BME rare or limited only to ventral & middle superior sacrum
Findings may improve MRI ID of axSpa
AbsPOS0193 @RheumNow #EULAR2026 https://t.co/7eiHQOOIWs
sheila RHEUMarampa ( View Tweet)
Gecacitinib 100mg BiD vs PBO in active r-axSpA:
Met primary endpt ASAS40 at wk 16 showing efficacy of gecacitinib vs. PBO (51.9%vs12.9%,p<0.0001)
Gecacitinib showed ⬆️ improvements in ASDAS-CRP, physical fnxn, spinal mobility & QOL
Promising tx.
AbsOP0240 @RheumNow #EULAR2026 https://t.co/FytoRgxvnG
Links:
sheila RHEUMarampa ( View Tweet)
Don't miss a single moment of #EULAR2026—RheumNow is bringing you comprehensive, real-time coverage from June 3-6. Our trusted global faculty will cut through the noise, translating the latest breaking data and complex science into high-yield, practical insights. Whether you are https://t.co/isBsTVnEcK
Dr. John Cush RheumNow ( View Tweet)
#OP0337 In 48-week WILLOW🌳 LTE, oral TLR7/8 inhibitor enpatoran showed sustained improvements in cutaneous lupus activity with high CLASI-50/70 response rates and consistent safety profile across doses. Encouraging long-term data for CLE/SLE skin disease. #EULAR2026 @RheumNow https://t.co/6y0HjaTMqh
Mrinalini Dey DrMiniDey ( View Tweet)
#EULAR2026 OP0337 In double blind LTE WILLOW study, cutaneous efficacy (change in CLASI, CLASI 70/50) was maintained in Enpatoran, TLR 7/8-i by WK48. Those switched from PBO to ENP at WK24 also showed equal efficacy to ENP-ENP group. Promising treatment for #CLE #lupus @RheumNow https://t.co/0Plpy6c8At
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Personalized #RA treatment based on Ab status and early response: better than routine care? PRIMERA RCT (n=308) says not yet. b/tsDMARD use at 10m: 21% tailored vs 17% routine. Disease activity curves identical. MTX + T2T still the standard for most. @RheumNow #EULAR2026 POS0258 https://t.co/W9FVoqTcMq
Jiha Lee JihaRheum ( View Tweet)
PET-derived parameters in #PsA correlated with DAPSA, CRP and patient pain. Angiogenesis imaging may be a complementary biomarker of overall disease burden Abstr#OP068 #EULAR2026 #Imaging
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
RheumNow’s expanded coverage of the #EULAR2026 annual meeting is sponsored by Bristol Myers Squibb and UCB. RheumNow and its faculty independently select all coverage content.
Dr. John Cush RheumNow ( View Tweet)
One of the main changes in the 2025 update on the EULAR guidelines for imaging in SpA is that of MRI replacing CR as the initial imaging modality while CR & low dose CT of SIJs became alternative modalities in the absence of or if with CIs to MRI
AbsPOS0682 @RheumNow #EULAR2026 https://t.co/bj2NWKnIGf
sheila RHEUMarampa ( View Tweet)
Treat-to-target in inflammatory arthritis recommended by every guideline. Followed in only 40% of SpA visits.
The main reason was activity simply wasn’t documented using a validated index.
You can’t target what you don’t measure.
Abstr 0351 @ RheumNow #EULAR2026
#axSpA #PsA https://t.co/VAcoZfCXsR
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
#OP0344 RADAR, AI-automated scoring of RA radiographic damage, was applied to 20yr ESPOIR imaging data. Strong performance vs expert readers, w binary classification accuracy up to 0.95 & ICC 0.86. Supports AI-assisted long-term structural assessment in RA. #EULAR2026 @RheumNow
Mrinalini Dey DrMiniDey ( View Tweet)
New Insights in Gout Clinical Management
https://t.co/Eo63NUhaY2 https://t.co/oHZG1c1LhL
Dr. John Cush RheumNow ( View Tweet)
